← Moderna

What podcasts say about Moderna

Every statement, with the speaker, the exact quote and the moment it was said.

What experts have said about Moderna

111 statements · 72 positive · 29 negative · 4 mixed · 6 neutral

  1. Tierney BaumPositiveNov 17, 2026· BioCentury This Week

    Moderna and Merck’s neoantigen program leads the pipeline with the most Phase 3 trials.

    “they're still clearly ahead in the pipeline. They have the most phase three trials.”

    Listen at 12:23

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  2. Tierney BaumNeutralNov 17, 2026· BioCentury This Week

    The Moderna and Merck program’s primary readout is not expected until 2028.

    “this one's still not going to reach its primary readout till 2028.”

    Listen at 12:30

    Open the episode · Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
  3. Jim CramerPositiveNov 13, 2026· Mad Money w/ Jim Cramer

    Moderna’s stock rose from $63 to above $174 in one day.

    “Moderna was a $63 stock. The next day, it closed above $174”

    Listen at 28:10

    Open the episode · NVIDIA Without Jensen, Anthropic IPO Risks & Moderna’s Cancer Vaccine 11/12/26
  4. Moderna’s melanoma treatment showed a 42% patient improvement versus Keytruda.

    “we were able to show a 42% improvement for patients.”

    Listen at 32:03

    Open the episode · NVIDIA Without Jensen, Anthropic IPO Risks & Moderna’s Cancer Vaccine 11/12/26
  5. Moderna’s melanoma vaccine data improves over time.

    “We show that the data improves over time.”

    Listen at 32:17

    Open the episode · NVIDIA Without Jensen, Anthropic IPO Risks & Moderna’s Cancer Vaccine 11/12/26
  6. Matthew CloutierPositiveNov 9, 2026· Breaking Biotech

    International COVID vaccine sales drove most of Moderna’s revenue increase

    “Most of the revenue, though, is due to the increase in international COVID vaccine sales.”

    Listen at 22:29

    Open the episode · 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026
  7. Matthew CloutierPositiveNov 9, 2026· Breaking Biotech

    Intismeran RCC data could materially move Moderna’s stock

    “that's going to be a big mover for the stock, in my opinion.”

    Listen at 23:48

    Open the episode · 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026
  8. Matthew CloutierPositiveNov 9, 2026· Breaking Biotech

    Moderna’s lipid-nanoparticle technology is well suited to propionic acidemia

    “Moderna's technology is uniquely suited for this”

    Listen at 24:55

    Open the episode · 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026
  9. Matthew CloutierPositiveNov 9, 2026· Breaking Biotech

    Positive propionic-acidemia results could expand Moderna into rare diseases

    “if they see a positive effect here, then they're also going to be able to include rare disease into their franchise.”

    Listen at 25:30

    Open the episode · 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026
  10. Matthew CloutierNegativeNov 9, 2026· Breaking Biotech

    Moderna’s high valuation depends on an unrealized, uncertain future

    “the company's got such a high valuation now on a reality that doesn't quite exist yet and might never exist.”

    Listen at 27:50

    Open the episode · 121 - Breaking Biotech Week End Wrap Up - Nov 7 , 2026
  11. Steve WeissNegativeNov 4, 2026· Halftime Report

    Moderna's stock price has risen ahead of fundamentals.

    “it's ahead of itself.”

    Listen at 28:45

    Open the episode · Post-Midterm Playbook 11/4/26
  12. Steve WeissNeutralOct 30, 2026· Halftime Report

    Moderna has 39 vaccines and drugs in its pipeline.

    “They've got 39 vaccines and drugs in the pipeline.”

    Listen at 26:41

    Open the episode · Amazon in Focus as the Nasdaq Slides 10/3026
  13. Selina KochNegativeOct 27, 2026· BioCentury This Week

    Moderna’s personalized vaccine currently takes about 42 days per dose to manufacture.

    “it takes right now something like 42 days to make a dose”

    Listen at 26:56

    Open the episode · Ep. 394 - Security concerns in U.S., China reshaping biotech
  14. Jim CramerPositiveOct 26, 2026· Mad Money w/ Jim Cramer

    Moderna is a high-quality company.

    “I like Moderna. I think it's a terrific company.”

    Listen at 7:20

    Open the episode · Mad Money w/ Jim Cramer 10/26/26
  15. Matthew CloutierPositiveOct 26, 2026· Breaking Biotech

    Moderna’s melanoma trial produced a recurrence-free survival hazard ratio of 0.58.

    “the intent to treat recurrence-free survival hazard ratio was 0.58”

    Listen at 7:27

    Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026
  16. Matthew CloutierPositiveOct 26, 2026· Breaking Biotech

    Two-year recurrence-free survival was 82.2% with treatment versus 70% for control.

    “the two-year recurrence-free survival, it was 82.2% for the treatment group versus 70%”

    Listen at 7:50

    Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026
  17. Matthew CloutierNegativeOct 26, 2026· Breaking Biotech

    Treatment-group adverse events caused more discontinuations than control-group events.

    “14% of the adverse events in the treatment group led to discontinuations as compared to only 8%”

    Listen at 8:39

    Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026
  18. Matthew CloutierNegativeOct 26, 2026· Breaking Biotech

    Moderna’s stock sell-off will probably continue.

    “the sell-off is probably going to continue”

    Listen at 12:32

    Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026
  19. Matthew CloutierPositiveOct 26, 2026· Breaking Biotech

    Non-small-cell lung cancer is Moderna’s major target indication.

    “The big dog, or at least the gold, the gold. medal that they're going to be trying to achieve is non-small cell lung cancer.”

    Listen at 13:07

    Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026
  20. Matthew CloutierNeutralOct 26, 2026· Breaking Biotech

    Moderna’s renal-cell-carcinoma trial is expected in early 2027.

    “the renal cell carcinoma trial that I believe is going to be released in early 2027”

    Listen at 13:38

    Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026
  21. Positive renal-cell-carcinoma data could sustain Moderna’s valuation.

    “if that seems to be particularly positive, then maybe you can sustain this valuation”

    Listen at 13:52

    Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026
  22. John CooganNeutralOct 23, 2026· TBPN

    Speculation that Moderna cured cancer drove major stock volatility.

    “the stock has been on this wild ride up and down, fueled by speculation that they cured cancer”

    Listen at 1:40

    Open the episode · Moderna Drama, WSJ Mansion Section, Genetically Engineered Military Dogs | Thomas Wright, Kyle Schiller, Steven Schwartz
  23. John CooganMixedOct 23, 2026· TBPN

    Moderna’s phase-three trial succeeded but underwhelmed investor expectations.

    “the phase three did succeed, but the results weren't as spectacular as investors had hoped.”

    Listen at 5:48

    Open the episode · Why Moderna Tanked, MSG Employees Duped By Their Boss, The Mansion Section | Diet TBPN
  24. Sam FazeliNegativeOct 23, 2026· Biotech Hangout

    Moderna’s valuation had reached a level requiring nearly perfect results.

    “it was getting to a point where you needed absolute perfection”

    Listen at 7:40

    Open the episode · Episode 200 - October 23, 2026
  25. Sam FazeliNegativeOct 23, 2026· Biotech Hangout

    Investors were seeking reasons to take profits after Moderna’s large increase.

    “all that's going on here is people have tried to find a reason to to take profit for something that's gone up i don't know 200 300 400 depending where you measure it from”

    Listen at 9:29

    Open the episode · Episode 200 - October 23, 2026
  26. John CooganPositiveOct 23, 2026· TBPN

    Moderna’s stock rose 25% over two weeks after Togi bought calls.

    “Over the next two weeks, the stock went up 25%.”

    Listen at 9:59

    Open the episode · Why Moderna Tanked, MSG Employees Duped By Their Boss, The Mansion Section | Diet TBPN
  27. Brad LoncarPositiveOct 23, 2026· Biotech Hangout

    Moderna’s stock remained above levels implied by the known trial success.

    “this is clearly above what people thought this could do”

    Listen at 10:46

    Open the episode · Episode 200 - October 23, 2026
  28. Brad LoncarNegativeOct 23, 2026· Biotech Hangout

    Moderna’s stock price had moved above expectations before the pullback.

    “this is clearly above what people thought this could do in the context of if you take a step out and look at it from a wider lens as opposed to what it was trading at the day before”

    Listen at 10:46

    Open the episode · Episode 200 - October 23, 2026
  29. John CooganNegativeOct 23, 2026· TBPN

    Moderna shares fell 26% shortly after trial results leaked.

    “Shortly after, the results were leaked and the stock crashed by 26%.”

    Listen at 11:16

    Open the episode · Why Moderna Tanked, MSG Employees Duped By Their Boss, The Mansion Section | Diet TBPN
  30. John CooganNegativeOct 23, 2026· TBPN

    Moderna’s stock fell 26% shortly after the trial results leaked.

    “Shortly after, the results were leaked and the stock crashed by 26%.”

    Listen at 11:16

    Open the episode · Why Moderna Tanked, MSG Employees Duped By Their Boss, The Mansion Section | Diet TBPN

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.